This HTML5 document contains 191 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
n10http://dx.doi.org/10.1158/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q34781067
rdf:type
wikibase:Item
schema:description
article científic artikull shkencor 2011年の論文 2011年论文 ২০১১-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ научни чланак scientific article artigo científico 2011年論文 мақолаи илмӣ teaduslik artikkel научна статия 2011년 논문 scienca artikolo mokslinis straipsnis artículo científico publicado en 2011 artículu científicu espublizáu en 2011 مقالهٔ علمی 2011年论文 wetenschappelijk artikel 2011年论文 wissenschaftlicher Artikel 2011 թուականի Յունուարին հրատարակուած գիտական յօդուած bilimsel makale naučni članak artikulong pang-agham 2011年論文 2011年论文 vetenskaplig artikel articol științific سائنسی مضمون мақолаи илмӣ 2011年論文 2011 թվականի հունվարին հրատարակված գիտական հոդված artigo científico (publicado na 2011) 2011年論文 tudományos cikk vedecký článok научная статья artykuł naukowy სამეცნიერო სტატია επιστημονικό άρθρο научни чланак vitskapeleg artikkel наукова стаття, опублікована в січні 2011 article scientifique (publié 2011) 2011年论文 articolo scientifico מאמר מדעי vědecký článek مقالة علمية บทความทางวิทยาศาสตร์ 2011 nî lūn-bûn article scientific vitenskapelig artikkel bài báo khoa học 2011年论文 tieteellinen artikkeli 2011年論文 videnskabelig artikel (udgivet 2011) artigo científico (publicado na 2011)
p:P577
wds:Q34781067-FC84DDE5-E9CC-4733-8730-26A72B918F5E
wdt:P577
2011-01-10T00:00:00Z
p:P407
wds:Q34781067-E565D274-F200-411B-A368-D75E45CAF582
wdt:P407
wd:Q1860
p:P2860
wds:Q34781067-63728ADA-0D93-4621-93EE-7999B25C154E wds:Q34781067-8362E0ED-9E49-4265-B7EE-C593E7D7CDD3 wds:Q34781067-B94E9721-3C34-4CC1-BAC9-89397811B793 wds:Q34781067-B9B8048D-39AF-429B-A64A-D6D927FD2A78 wds:Q34781067-CCC51BC7-182B-4A46-9D88-FFAF2E9539B0 wds:Q34781067-AA710F4C-4DC8-422D-A3B3-956AECBA9846 wds:Q34781067-AC03BC0D-C897-47AF-AED1-528E53714F9F wds:Q34781067-B1959A63-BF16-46E2-A9BC-A0C5E9F94AC0 wds:Q34781067-B2EC89C9-31E6-4B04-AC88-54815528ED92 wds:Q34781067-B72517D8-2ED5-4C38-9AF2-D19B4085292B wds:Q34781067-B794EA62-3ED2-40F6-9F49-16618CF70C6A wds:Q34781067-D1A174BF-CFDA-40EF-BBAC-1E511B4C7969 wds:Q34781067-E705C0DE-1403-4222-99D5-1717EF07E5A1 wds:Q34781067-16769886-8180-4B7F-8013-BE60593595BA wds:Q34781067-2BB02D96-D44E-4A36-B1EA-7F2360400B24 wds:Q34781067-2C3D8223-F614-48A5-9B9A-94765B44DB2C wds:Q34781067-2F0F1436-401D-4CE0-A36A-7A3EA2C844B8 wds:Q34781067-3606D625-0497-4DB1-9CC2-FB201DF95B68 wds:Q34781067-02ABAAE8-EE39-4E50-BBF0-A0A09CF75CBE wds:Q34781067-05C6A561-E46F-42EF-A5F2-52CC41B66C48 wds:Q34781067-05F8DEE2-239E-46A6-B404-9D4493D7CD61 wds:Q34781067-06166892-67DC-4F8F-83E7-7155A6660CE0 wds:Q34781067-12F10FEB-E35A-41D9-88E3-6D0E96A77B44 wds:Q34781067-13D2A4C3-BCA8-4D0A-BB62-80ECE341F8DA wds:Q34781067-85E095F3-8202-4284-91C7-3108390A05B2 wds:Q34781067-896625F1-F997-41A1-9BCA-1D688BE1D6A2 wds:Q34781067-98D1CE67-4C0C-4A72-B612-78F8139C6FB2 wds:Q34781067-A8229D7C-6766-4E0A-8F60-08AC7830E8E3 wds:Q34781067-A93FAF45-5B29-495B-896D-4DB1B1A200E4 wds:Q34781067-4C53F7E0-CA47-4989-9F4B-B36C36A17692 wds:Q34781067-54C54187-93FE-4094-B385-68872F030D8A
wdt:P2860
wd:Q40637109 wd:Q40138970 wd:Q40270968 wd:Q95818649 wd:Q71751787 wd:Q40670668 wd:Q24563115 wd:Q46586619 wd:Q46542698 wd:Q33181833 wd:Q43969830 wd:Q52030096 wd:Q40408917 wd:Q43270036 wd:Q34394358 wd:Q29547513 wd:Q45309214 wd:Q42807740 wd:Q40544950 wd:Q43824354 wd:Q43136784 wd:Q34745057 wd:Q57578634 wd:Q46847543 wd:Q33749611 wd:Q80139015 wd:Q40243239 wd:Q36466862 wd:Q45050365 wd:Q77598704 wd:Q41188292
p:P2093
wds:Q34781067-FFF8E8FA-B389-4D57-9334-F288788C1136 wds:Q34781067-E1EEBEF9-C73E-442B-9EA3-228C429E7DC5 wds:Q34781067-E4A76DF6-332E-4728-9A00-E0999467411E wds:Q34781067-BC6BB76D-BF96-4C96-8DFA-A40A6956FDA4 wds:Q34781067-8C3F4B73-AE71-4FBC-B5FD-09B1FA289971 wds:Q34781067-82D11E9A-401C-4F8B-B78B-1F720CB5B995 wds:Q34781067-637A08D7-265F-4334-9334-F9F546B8327B wds:Q34781067-7569B51F-A830-4C14-8401-1CA0F430B517 wds:Q34781067-40F9EC45-563F-4082-97F9-901D45BA0D87 wds:Q34781067-303E8D95-A40A-4B24-8FDD-D36D7521B47A wds:Q34781067-0562861D-BA8F-4257-94A4-1FD89217AED9
wdt:P2093
Carolina Gutierrez Luc Y Dirix Valsamo K Anagnostou Craig Underhill Patrick Magill Jean Robert David L Rimm Mark Sellers Ilenia Migliaccio John R Mackey C Kent Osborne
rdfs:label
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study
skos:prefLabel
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study
schema:name
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study
p:P50
wds:Q34781067-C91B5A63-8159-4053-870C-DC411E093970 wds:Q34781067-FAC4DA11-5615-4317-AD32-5B72D67C0371
wdt:P50
wd:Q90004173 wd:Q90949247
p:P1476
wds:Q34781067-355005D4-8F28-491A-88A6-694F5858CBCB
wdt:P1476
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study
p:P304
wds:Q34781067-8E4D3E76-3B84-4273-9D85-D7DFA1576A57
wdt:P304
1147-1159
p:P31
wds:Q34781067-CB5EEE06-3F2C-41A6-89E5-B28E5568B313
wdt:P31
wd:Q13442814
p:P921
wds:Q34781067-E704A007-D70B-4879-946D-CC23407BA458 wds:Q34781067-D813E4D8-1EEE-41D9-AB4C-E2B7B4CBB318 wds:Q34781067-B74C53A6-4021-416D-B9D1-67CB8FB6AE67
wdt:P921
wd:Q412178 wd:Q12859063 wd:Q269829
p:P698
wds:Q34781067-BCA09C26-9CFB-4B64-8267-08FB66AECD7C
wdtn:P698
n12:21220480
wdt:P698
21220480
p:P1433
wds:Q34781067-F4F1B665-2A72-446D-BA5D-EE1C5704772D
wdt:P1433
wd:Q332253
p:P433
wds:Q34781067-15FACF5D-8776-43DE-8F3D-6C1F8604CE30
p:P478
wds:Q34781067-9A96EDAF-DC84-4227-AAC8-963FB4C5F22B
wdt:P433
5
wdt:P478
17
p:P356
wds:Q34781067-BA25C2B8-4BBC-4E0F-815E-C6DE9620933B
wdtn:P356
n10:1078-0432.CCR-10-1869
wdt:P356
10.1158/1078-0432.CCR-10-1869
p:P5875
wds:Q34781067-282ECC68-A187-44C6-BFFF-184F1EB73C1E
wdt:P5875
49742075
p:P932
wds:Q34781067-B3AB318E-D929-403E-BDEF-CADA5A3DA87E
wdt:P932
3074404